Pityriasis rosea following human papillomavirus vaccination

Drago, Francesco; Ciccarese, Giulia; Rebora, Alfredo; Parodi, Aurora

doi:10.1016/j.bjid.2014.10.006

Cited by 11 publications

(5 citation statements)

References 5 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pityriasis rosea has been documented as an additional adverse reaction to HPV vaccination in the literature. It has also been exceedingly rare but sporadically reported following vaccinations against diphtheria, tuberculosis, poliomyelitis, and tetanus [ 107 ].…”

Section: Discussionmentioning

confidence: 99%

Unveiling the Therapeutic Horizon: HPV Vaccines and Their Impact on Cutaneous Diseases—A Comprehensive Review

Șandru,

Radu,

Petca

et al. 2024

Vaccines

View full text Add to dashboard Cite

Human papillomavirus (HPV) encompasses a diverse array of viruses, comprising approximately 200 serotypes that affect humans. While the majority of HPV strains are associated with benign skin or mucous membrane growths, a subset is implicated in severe health conditions, such as cervical, anal, vulvar, and vaginal cancers. Despite the established effectiveness of HPV vaccines in preventing cervical and anal carcinomas in particular, their therapeutic potential in addressing cutaneous diseases linked to diverse HPV strains remains an intriguing area of investigation. This narrative review critically examines the existing literature to assess the viability of HPV immunization as a therapeutic intervention for prevalent cutaneous conditions. These include genital and extragenital cutaneous warts, epidermodysplasia verruciformis, and keratinocyte carcinomas. The findings suggest a promising dual role for HPV vaccines in preventing and treating dermatologic conditions while emphasizing future research directions, including the immunization perspective against β-HPVs. Moreover, the presence of conflicting study outcomes underscores the imperative for larger-scale, randomized trials with well-matched control groups to validate the efficacy of HPV immunization in the dermatologic context. This review contributes valuable insights into the evolving landscape of HPV-vaccine applications in the field of dermatology.

show abstract

Section: Discussionmentioning

confidence: 99%

Unveiling the Therapeutic Horizon: HPV Vaccines and Their Impact on Cutaneous Diseases—A Comprehensive Review

Șandru,

Radu,

Petca

et al. 2024

Vaccines

View full text Add to dashboard Cite

show abstract

“…Cases of PR and PR-like reactions concurrent with COVID-19 have been described as well in the literature. 32 , 66 , 67 There have also been reports of PR or PR-like reactions after vaccination for human papillomavirus, 68 bacillus Calmette-Guérin, 69 smallpox, 70 hepatitis B, 71 pneumococcus, 72 yellow fever, 73 and influenza. 74 , 75 …”

Section: Discussionmentioning

confidence: 99%

Pityriasis following COVID-19 vaccinations: a systematic review

Duzett,

Mercado,

Tasouli-Drakou

et al. 2023

Dermatol Reports

View full text Add to dashboard Cite

In the wake of a global COVID-19 pandemic, where innovations in vaccination technology and the speed of development and distribution have been unprecedented, a wide variety of post-vaccination cutaneous reactions have surfaced. However, there has not been a systematic review that investigates pityriasis eruptions and the associated variants following COVID-19 inoculations. A PubMed search using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) was performed to find case reports from the earliest record through November 2022. Data including types of vaccination and pityriasis were extracted and a quality review was performed. 47 reports with 94 patients were found: 64.9% had pityriasis rosea (PR), 3.2% PR-like eruptions, 16.0% pityriasis rubra pilaris (PRP), 7.4% pityriasis lichenoides et varioliformis acuta (PLEVA), 3.2% pityriasis lichenoides chronica (PLC), and 5.3% had reactions described as “atypical”. The top three COVID-19 vaccinations reported were Pfizer-BioNTech (47.9%), Oxford-AstraZeneca (11.7%), and Moderna (8.5%). Pityriasis reactivity was reported most frequently after the Pfizer-BioNTech vaccination, with pityriasis rosea being the most common variant. A large difference was additionally found between the ratio of post-vaccination pityriasis reactions following Pfizer and Moderna vaccinations (5.63), and the ratio of Pfizer’s usage in the United States as of December 28, 2022 relative to that of Moderna (1.59). Further studies with adequate follow-up periods and diagnostic testing will thus need to be performed to elucidate the root of this discrepancy and better characterize the association between different pityriasis reactions and COVID-19 vaccinations.

show abstract

“…One of the hypotheses regarding this association is that a high cytokine response to the vaccine distracts the Tcellemediated control of latent infections, such as human herpes virus 6 and 7 and, hence, the reactivation of the latent viruses. [70][71][72] In contrast, pityriasis rosea-like eruptions following COVID-19 vaccination may have a different pathophysiology. These have been postulated to be a manifestation of a delayed hypersensitivity response to the vaccine.…”

Section: Discussionmentioning

confidence: 99%

Cutaneous reactions to COVID-19 vaccines: A review

Wei¹

2022

JAAD International

View full text Add to dashboard Cite

Pityriasis rosea following human papillomavirus vaccination

Cited by 11 publications

References 5 publications

Unveiling the Therapeutic Horizon: HPV Vaccines and Their Impact on Cutaneous Diseases—A Comprehensive Review

Unveiling the Therapeutic Horizon: HPV Vaccines and Their Impact on Cutaneous Diseases—A Comprehensive Review

Pityriasis following COVID-19 vaccinations: a systematic review

Cutaneous reactions to COVID-19 vaccines: A review

Contact Info

Product

Resources

About